These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10326267)

  • 1. Should smoking cessation cost a packet? A pilot randomized controlled trial of the cost-effectiveness of distributing nicotine therapy free of charge.
    Dey P; Foy R; Woodman M; Fullard B; Gibbs A
    Br J Gen Pract; 1999 Feb; 49(439):127-8. PubMed ID: 10326267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost effectiveness of pharmacotherapies for smoking cessation: necessary but not sufficient?
    Shanahan M; Doran C; Gates J; Shakeshaft A; Mattick RP
    Appl Health Econ Health Policy; 2003; 2(2):76-8. PubMed ID: 14619277
    [No Abstract]   [Full Text] [Related]  

  • 3. The cost-effectiveness of the nicotine transdermal patch for smoking cessation.
    Wasley MA; McNagny SE; Phillips VL; Ahluwalia JS
    Prev Med; 1997; 26(2):264-70. PubMed ID: 9085397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness of the methods of smoking cessation].
    Plans P; Navas E; Tarín A; Rodríguez G; Galí N; Gayta R; Taberner JL; Salleras L
    Med Clin (Barc); 1995 Jan; 104(2):49-54. PubMed ID: 7869779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of the nicotine patch.
    Stevermer J
    J Fam Pract; 1996 Aug; 43(2):125-6. PubMed ID: 8708620
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of transdermal nicotine patches for nicotine replacement and smoking cessation.
    Holdcroft C
    Nurse Pract; 1992 Jul; 17(7):46-8. PubMed ID: 1495597
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effective primary care-based strategies to improve smoking cessation: more value for money.
    Salize HJ; Merkel S; Reinhard I; Twardella D; Mann K; Brenner H
    Arch Intern Med; 2009 Feb; 169(3):230-5; discussion 235-6. PubMed ID: 19204212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The benefits of switching smoking cessation drugs to over-the-counter status.
    Keeler TE; Hu TW; Keith A; Manning R; Marciniak MD; Ong M; Sung HY
    Health Econ; 2002 Jul; 11(5):389-402. PubMed ID: 12112489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries.
    Bolin K; Wilson K; Benhaddi H; de Nigris E; Marbaix S; Mork AC; Aubin HJ
    Eur J Public Health; 2009 Dec; 19(6):650-4. PubMed ID: 19491286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation.
    Nielsen K; Fiore MC
    Prev Med; 2000 Mar; 30(3):209-16. PubMed ID: 10684744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicotine patches and uninsured quitline callers. A randomized trial of two versus eight weeks.
    McAfee TA; Bush T; Deprey TM; Mahoney LD; Zbikowski SM; Fellows JL; McClure JB
    Am J Prev Med; 2008 Aug; 35(2):103-10. PubMed ID: 18617079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smoking cessation in a blue-collar population: results from an evidence-based pilot program.
    Ringen K; Anderson N; McAfee T; Zbikowski SM; Fales D
    Am J Ind Med; 2002 Nov; 42(5):367-77. PubMed ID: 12382249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Methods and cost effectiveness of nicotine abstinence].
    Górecka D
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():79-82. PubMed ID: 15524024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dependence potential of nicotine replacement treatments: effects of product type, patient characteristics, and cost to user.
    Hajek P; McRobbie H; Gillison F
    Prev Med; 2007 Mar; 44(3):230-4. PubMed ID: 17207524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of offering free transdermal nicotine patches on quit rates in a local health department's smoking cessation program.
    Alberg AJ; Stashefsky Margalit R; Burke A; Rasch KA; Stewart N; Kline JA; Ernst PA; Avey A; Hoffman SC
    Addict Behav; 2004 Dec; 29(9):1763-78. PubMed ID: 15530720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Australian smokers' use of bupropion and nicotine replacement therapies and their relation to reimbursement, Australia 2001-05.
    Lutsenko H; Doran CM; Hall WD
    Drug Alcohol Rev; 2008 Mar; 27(2):160-4. PubMed ID: 18264876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should managed care organizations pay for nicotine replacement therapy?
    Westman EC
    Am J Manag Care; 1997 Feb; 3(2):335-7. PubMed ID: 10169267
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of varenicline for smoking cessation.
    Keiding H
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):215-21. PubMed ID: 19527093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-effectiveness evaluation of single and combined smoking cessation interventions in Texas.
    Hill A
    Tex Med; 2006 Aug; 102(8):50-5. PubMed ID: 17115560
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of a free nicotine patch starter kit on quit rates in a state quit line.
    Bush TM; McAfee T; Deprey M; Mahoney L; Fellows JL; McClure J; Cushing C
    Nicotine Tob Res; 2008 Sep; 10(9):1511-6. PubMed ID: 19023843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.